Larkin J - Search Results

1

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.

Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia; Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA. Arce Vargas F, et al. Among authors: larkin j. Cancer Cell. 2018 Apr 9;33(4):649-663.e4. doi: 10.1016/j.ccell.2018.02.010. Epub 2018 Mar 22. Cancer Cell. 2018. PMID: 29576375 Free PMC article.

2

The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress.

Larkin JM, Gore ME. Larkin JM, et al. Clin Oncol (R Coll Radiol). 2005 Aug;17(5):319-21. doi: 10.1016/j.clon.2005.03.007. Clin Oncol (R Coll Radiol). 2005. PMID: 16097560 No abstract available.

3

Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanoma.

Larkin JM, Norsworthy PJ, A'Hern RP, Eisen TG, Gore ME, Porter CD. Larkin JM, et al. Melanoma Res. 2006 Apr;16(2):157-63. doi: 10.1097/01.cmr.0000200490.62723.b0. Melanoma Res. 2006. PMID: 16567971

4

A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.

Larkin JM, Hughes SA, Beirne DA, Patel PM, Gibbens IM, Bate SC, Thomas K, Eisen TG, Gore ME. Larkin JM, et al. Br J Cancer. 2007 Jan 15;96(1):44-8. doi: 10.1038/sj.bjc.6603503. Epub 2006 Dec 5. Br J Cancer. 2007. PMID: 17146474 Free PMC article. Clinical Trial.

5

Drug insight: advances in renal cell carcinoma and the role of targeted therapies.

Larkin JM, Chowdhury S, Gore ME. Larkin JM, et al. Nat Clin Pract Oncol. 2007 Aug;4(8):470-9. doi: 10.1038/ncponc0901. Nat Clin Pract Oncol. 2007. PMID: 17657252 Review.

6

Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.

Chowdhury S, Larkin JM, Gore ME. Chowdhury S, et al. Eur J Cancer. 2008 Oct;44(15):2152-61. doi: 10.1016/j.ejca.2008.06.028. Epub 2008 Sep 29. Eur J Cancer. 2008. PMID: 18829302 Review.

7

Sunitinib is superior to interferon alpha with respect to quality of life for patients with renal cell carcinoma.

Pickering LM, Pyle L, Larkin JM. Pickering LM, et al. Nat Clin Pract Oncol. 2009 Jan;6(1):6-7. doi: 10.1038/ncponc1283. Nat Clin Pract Oncol. 2009. PMID: 19096396

8

Malignant melanoma (metastatic).

Larkin J, Gore M. Larkin J, et al. BMJ Clin Evid. 2008 Aug 22;2008:1718. BMJ Clin Evid. 2008. PMID: 19445806 Free PMC article. Review.

9

Health policy: The UK 'postcode lottery' in renal cell carcinoma.

Larkin J, Gore M. Larkin J, et al. Nat Rev Urol. 2009 Dec;6(12):636-8. doi: 10.1038/nrurol.2009.228. Nat Rev Urol. 2009. PMID: 19956190 No abstract available.

10

Is advanced renal cell carcinoma becoming a chronic disease?

Larkin J, Gore M. Larkin J, et al. Lancet. 2010 Aug 21;376(9741):574-5. doi: 10.1016/S0140-6736(10)60816-1. Lancet. 2010. PMID: 20728740 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,231 results

Search Page